HHS Six-Peptide Compounding Policy (2026) | Dose Track
[News · Regulation]

HHS Six-Peptide Compounding Policy (2026): What the Draft Actually Says

Docket HHS-OASH-2026-0496 · Published October 30, 2026 · BPC-157, epitalon, KPV, MOTS-c, semax, TB-500

Published · By Ethen Amezquita

Short answer: On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The policy covers one salt form and set routes for each, and applies only when ten conditions are met, including a patient-specific prescription and one peptide per product. It does not put any of them on FDA's 503A bulks list and does not make them FDA approved. Comments on docket HHS-OASH-2026-0496 close on November 13, 2026.

All facts below come from the Federal Register notice, the HHS policy and its Appendix B, read on November 11, 2026. This is a summary of a government document, not legal or medical advice.

What HHS published, and when

The Federal Register notice (FR Doc. 2026-22192, 91 FR 68526) was filed on October 28, 2026 and published on October 30, 2026. It is signed by HHS Secretary Robert F. Kennedy, Jr. and announces a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." The notice says the draft "is not binding on HHS or the public" and that HHS may revisit it if "a safety signal or product quality issue arises."

Comments go to regulations.gov on docket HHS-OASH-2026-0496. The notice gives two weeks from publication, and the docket lists the comment period as ending on November 13, 2026.

Note the sender. This came from the HHS Secretary's office, not from FDA. In July 2026, FDA's own staff recommended against adding all seven peptides it reviewed to the 503A bulks list (see our post on that meeting).

The six peptides, forms and routes

The policy lists six peptides in Appendix A. Appendix B then limits each one to a single form and set routes:

PeptideForm coveredRoutes covered
BPC-157AcetateUnder the skin, into muscle, by mouth, on the skin
TB-500AcetateUnder the skin or into muscle
EpitalonAcetateUnder the skin or into muscle, in intermittent courses
SemaxFree baseIn the nose
KPVAcetateOn the skin and by mouth
MOTS-cAcetateUnder the skin or into muscle

So the policy does not cover, for example, injected KPV or injected semax. Appendix B also fixes each peptide's identity: amino acid sequence, molecular formula and molecular weight.

The ten conditions

HHS says it does not intend to act only "when all of the following circumstances are present." In plain words:

  1. The peptide is on the Appendix A list.
  2. It matches the identity and routes in Appendix B.
  3. The raw ingredient comes from an FDA-registered facility, with a valid certificate of analysis showing tests for identity, purity, potency and contaminants such as endotoxins and heavy metals. Our COA guide explains those tests.
  4. The original maker is FDA-registered, follows manufacturing rules (CGMP) and is named, with its location, on the certificate.
  5. The compounder reports products made, serious adverse events and quality problems to FDA's MedWatch program and to the states involved, and the patient's label explains how to report problems.
  6. The label says: "This is a compounded drug product. Not for resale."
  7. Each product contains only one listed peptide. No blends.
  8. For any oral form, the compounder keeps records showing the formula reaches "an adequate level of oral bioavailability in humans."
  9. The only device allowed is an FDA 510(k)-cleared syringe.
  10. Everything else in the law still applies, including clean conditions and a valid patient-specific prescription.

Why HHS says it acted

The policy says it aims to discourage use of "research-use-only peptides supplied by foreign manufacturers" and to give patients "a more controlled alternative." It cites the July 2026 advisory committee and data on how often the peptides are used.

Appendix B gives a three-part reason for each peptide. The common threads: use is now documented, and newer certificates of analysis from FDA-registered sites fill testing gaps FDA staff had flagged. For TB-500, epitalon, semax and KPV, HHS describes FDA's safety concerns as inferential, mechanistic or based on missing information, rather than on observed harm. Appendix B also states that the advisory committee voted in favor of each of the six.

Where FDA's own review landed

FDA's July 2026 briefing documents found that "a balancing of the criteria weighs against" listing each peptide. For MOTS-c, for example, FDA's review said it was "particularly concerned about the lack of human data" and found no clinical studies. Appendix B instead points to newer documents; for BPC-157 it cites "evidence that was not before" FDA's drug center. Our MOTS-c trials post, BPC-157 evidence post and TB-500 post cover the human data.

What the policy does not do

  • It is not a listing. The six are still not on the 503A bulks list. The notice says "FDA's future rulemakings may propose adding some or all." The policy runs until each peptide "is addressed in a final rule."
  • It is not an approval. The notice repeats that compounded drugs "are not FDA-approved," so FDA has not reviewed their safety, effectiveness or quality.
  • It does not cover research-use-only sellers. It applies to pharmacies, federal facilities and physicians filling a prescription. FDA has kept sending warning letters to online sellers in 2026; see our count of those letters.
  • It does not cover blends or pens. One peptide per product, and only a 510(k)-cleared syringe as the device.
  • It does not cover the other withdrawn peptides, such as GHK-Cu, ipamorelin or CJC-1295, which are not in Appendix A.

What this means for you

  • Talk to your clinician before starting, changing or stopping any of these. Human data on all six is thin, and this page gives no dosing.
  • A product made under this policy should carry the "compounded drug product" label line and come with a prescription in your name.
  • If something goes wrong, you can report it yourself to FDA MedWatch.
  • Keep the pharmacy label, lot number and certificate of analysis. Policies like this can change, and those records are what you and your clinician will need.

Frequently asked questions

Did HHS legalize BPC-157 in 2026?+
No. On October 30, 2026 HHS published a draft enforcement discretion policy. It says HHS does not intend to act against pharmacies, federal facilities or physicians that compound BPC-157 acetate under ten conditions. BPC-157 is still not on the 503A bulks list and is not FDA approved.
Which peptides are in the HHS policy?+
Six: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Each is limited to one form and set routes. Semax is covered only in the nose, and KPV only on the skin and by mouth.
When do comments on the HHS peptide policy close?+
The Federal Register notice allows two weeks from its October 30, 2026 publication. Regulations.gov lists the comment period for docket HHS-OASH-2026-0496 as ending on November 13, 2026.
Can a pharmacy make a peptide blend under the HHS policy?+
No. One condition is that the compounded product contains only a single active ingredient from the Appendix A list, so multi-peptide blends fall outside it.
Does the HHS policy cover research use only peptides sold online?+
No. It covers compounding by state-licensed pharmacies, federal facilities and licensed physicians with a patient-specific prescription. HHS says one aim is to move people away from research-use-only peptides from foreign makers.
Is the HHS peptide policy permanent?+
No. It is a draft and is not binding. It lasts until FDA addresses each peptide in a final rule, and HHS says it may revisit it if a safety signal or quality problem appears.

Sources

Every fact in this article comes from one of these sources, checked on November 11, 2026. This article is for education. It is not medical or legal advice, and nothing here is a dose recommendation.

  1. Federal Register. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice of availability, Docket No. HHS-OASH-2026-0496, FR Doc. 2026-22192, 91 FR 68526, October 30, 2026. federalregister.gov · PDF
  2. U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy and Appendix A). hhs.gov
  3. U.S. Department of Health and Human Services. Appendix B: Peptide Identities and Justifications for Placement of Peptide Bulk Drug Substances. hhs.gov · combined version linked from the notice: hhs.gov
  4. Regulations.gov. Docket HHS-OASH-2026-0496 (comment period dates). regulations.gov
  5. U.S. Food and Drug Administration. FDA Briefing Document, MOTS-c-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov/media/193347/download
  6. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
  7. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov